SecBot SecBot
COURT-RULING ·Filed Nov 13, 2026

NVO

NOVO NORDISK A S
NEUTRAL
Impact 3/10
Horizonweeks Processed2d 10h ago CourtCourt Ruling · govinfo.gov
Court ruling (district)
Actionable Insight • Neutral

The liability ruling is a positive step for Novo Nordisk in protecting its GLP-1 franchise from compounded semaglutide sellers, but the financial impact depends on the remedies phase. Monitor for the court's decision on disgorgement and injunctive relief, which could set a precedent for similar cases.

DirectionNeutral
Confidencehigh
Horizonweeks

Drug in focus

NVO drug pipeline →

Wegovy

● Neutral Named in this court ruling
Impact
Phase
Approved
Time to market
Already approved and marketed (injectable since 2021; oral pill since January 2026).
Next catalyst
None dated

What to watchThe next major catalyst for NVO shares tied to Wegovy is the Q3 2026 earnings report expected around November 4, 2026, where investors will scrutinize oral Wegovy pill sales trajectory and whether injectable Wegovy market share is stabilizing against Zepbound competition. Longer-term, watch for China approval of oral Wegovy and the Viatris patent challenge.

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

A federal magistrate judge recommended granting summary judgment on liability to Novo Nordisk against MD Exam LLC for trademark infringement, false advertising, and unfair competition related to MD Exam's unauthorized use of the Ozempic and Wegovy marks to sell compounded semaglutide. The ruling is on liability only; remedies (disgorgement, corrective advertising, injunctive relief) will be determined in further proceedings.

Court Ruling Details

Ruling Date
Nov 13, 2026
Court
United States District Court Southern District of Florida
Court Level
District
Judge
Detra Shaw-Wilder (Magistrate Judge)
Case Type
patent
Ruling Type
summary judgment
Outcome
WIN: ruling favors this company
Appeal Status
Interlocutory (case continues)
Precedent Risk
LOW

Key Facts

  • Novo Nordisk granted summary judgment on liability for all five counts (trademark infringement, unfair competition, false advertising, Florida common law unfair competition, FDUTPA).
  • MD Exam used Ozempic and Wegovy marks to advertise compounded semaglutide products without authorization.
  • Survey evidence showed 67.4% to 82.6% of consumers were confused into believing MD Exam's products were Ozempic or equivalent.
  • Remedies (disgorgement, corrective advertising costs, injunctive relief) reserved for further proceedings.
  • MD Exam served approximately 8,000 patients by May 2024.

Financial Impact

No damages or disgorgement amount awarded yet; remedies to be determined in subsequent proceedings.

revenuegoodwill

Risk Factors

  • The ruling is a recommendation by a magistrate judge, subject to district judge approval and potential objections within 14 days.
  • Remedies phase may result in limited monetary recovery if MD Exam has insufficient assets.
  • The ruling does not directly affect Novo Nordisk's core revenue from Ozempic/Wegovy sales.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
28% bullish (36 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 court opinion.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-cee6e876c9-NVO

Track record

43 reports on NVO

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +23.56% at T+60 after the Jul 28, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Neutral 2/10 Entry $41.89 Now $41.60 −0.69% settles Dec 15
  2. Nov 13, 20264d ago Court Ruling Neutral 3/10 Viewing Entry $42.01 Now $41.60 −0.98% settles Dec 15
  3. Nov 13, 20264d ago Court Ruling Neutral 1/10 Entry $42.01 Now $41.60 −0.98% settles Dec 15
  4. Nov 9, 20267d ago 6-K Neutral 2/10 Entry $41.38 Now $41.60 +0.53% settles Dec 8
  5. Nov 5, 202611d ago Institutional Cluster Neutral 2/10 Entry $40.30 Now $41.60 +3.23% settles Dec 4
  6. Nov 5, 202611d ago 6-K Neutral 2/10 Entry $40.30 Now $41.60 +3.23% settles Dec 4
  7. Nov 4, 202612d ago 6-K Bullish 6/10 Entry $42.18 Now $41.60 −1.38% settles Dec 3
  8. Nov 3, 202613d ago 6-K Neutral 2/10 Entry $40.19 Now $41.60 +3.51% settles Dec 2
  9. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $39.13 Now $41.60 +6.31% settles Nov 23
  10. Oct 26, 202622d ago Court Ruling Neutral 4/10 Entry $38.67 Now $41.60 +7.58% settles Nov 24
Showing 10 of 43

US Market Status

Market Closed · Opens in 5h 32m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · govinfo.gov Report published Nov 14, 2026